• Explore /
  • Poster
  • / TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

Abstract Poster

Authors

Charles Ryan

Charles J. Ryan

UC San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Charles J. Ryan , Wassim Abida , Alan Haruo Bryce , Arjun Vasant Balar , Igor Dumbadze , Robert W. Given , David Morris , Daniel Peter Petrylak , Charles H. Redfern , Howard I. Scher , Simon Paul Watkins , Andrew Simmons , Luke Passler , Tony Golsorkhi , Simon Chowdhury

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02975934

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS389)

DOI

10.1200/JCO.2018.36.6_suppl.TPS389

Abstract #

TPS389

Poster Bd #

P7

Abstract Disclosures

Similar Posters

First Author: Charles J. Ryan

First Author: Wassim Abida

First Author: Benedito A. Carneiro

First Author: Johann S. De Bono